SOURCE-LINKED INTELLIGENCE

Improving treatment efficacy in hypertension by biomarker-guided personalised decision support

CORDIS · observation · Publication date unknown

sis is that MOMICS biomarkers reflect specific forms of hypertension and susceptibility to specific drugs. To this end, we will run three clinical trials (HT-ENDO, HT-TREAT and HT-PREDICT) and apply machine learning techniques to integrate the genetic, genomic and metabolomic features that constitute the MOMICS biomarkers in order to generate accurate diagnostic and therapeutic response predictions for clinicians. We will also perform economic evaluation of the use of MOMICS for the treatment of HT, produce ethical and legal recommendations for clinical decision making, and develop a plan for their implementation as companion diagnostics. The study will be conducted by several HT Centres of Excellence and will build on the success of the ENSAT-HT project that has established methods and pipelines for integrating datasets derived from multiple platforms. We expect that HT-ADVANCE will provide a step change in the management of HT by enabling a personalised, more efficient and cost-effective treatment strategy, and importantly, will prevent the ensuing cardio-metabolic complications

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

8649616.25

unit

EUR